A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2012
At a glance
- Drugs PSN 010 (Primary) ; Glibenclamide
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 02 Sep 2010 Planned end date changed from 1 Mar 2011 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 25 Jun 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.